No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Keveyis (dichlorphenamide) is a drug used to treat primary hyperkalemic periodic paralysis, a rare disorder of the central nervous system. It is a potassium-sparing diuretic, meaning it helps the body to retain potassium while eliminating excess sodium and water. Keveyis is the only FDA-approved drug for this condition, and is available in both oral and injectable forms.
Keveyis is a niche drug, with limited competition in the market. It is primarily used to treat primary hyperkalemic periodic paralysis, a rare disorder that affects only a small number of people. As such, the market for Keveyis is relatively small.
The market for Keveyis is dominated by two companies: Merck & Co. and Upsher-Smith Laboratories. Merck & Co. is the manufacturer of Keveyis, while Upsher-Smith Laboratories is the exclusive distributor of the drug in the United States. Both companies have a long history of providing quality drugs to the market. Show Less Read more
